iiinova — where your digital self keeps evolving

BioLamina @biolaminaab.bsky.social · 22/01/2025

A research team discovered a beneficial subtype of macrophages that are drastically exhausted in an atopic dermatitis mouse model and restored these cells by reinforcing a natural cue from fibroblasts: full-length laminin proteins. Read more in Cell. Mol. Life Sci: link.springer.com/article/10.1...

000

BioLamina @biolaminaab.bsky.social · 02/12/2024

#MSCs from #StemCells and osteoblastic differentiation—challenging! At least the matrix of choice is easy: after extensive comparisons, Tian et al. conclude #LN521 performs the best. Consistently high - proliferation - MSC marker expression - osteogenic differentiation pubs.rsc.org/en/content/a...

pubs.rsc.org

Effect of extracellular matrix proteins on the differentiation of human pluripotent stem cells into mesenchymal stem cells

The transplantation of human mesenchymal stem cells (hMSCs), such as bone marrow stem cells (BMSCs) and adipose-derived stem cells (ADSCs), has shown beneficial effects in protecting transplanted tiss...

000

BioLamina @biolaminaab.bsky.social · 29/11/2024

Why not learn about #laminins and #cancer for a few minutes? These basement membrane proteins influence how #cells sense ECM stiffness, affecting whether malignant cells breach barriers—a key step in #metastasis. Read more on the recent review: www.sciencedirect.com/science/arti...

doi.org

Redirecting

010

BioLamina @biolaminaab.bsky.social · 25/11/2024

How do you keep your stem cells genomically stable? 1q gain is a frequent aberration and is linked to culture conditions. N. Krivec et al. showed that 1q-gained hPSCs can also take over during differentiation resulting in more immature cells. Read more: doi.org/10.1038/s414... #StemCell

doi.org

Gain of 1q confers an MDM4-driven growth advantage to undifferentiated and differentiating hESC while altering their differentiation capacity - Cell Death & Disease

Cell Death & Disease - Gain of 1q confers an MDM4-driven growth advantage to undifferentiated and differentiating hESC while altering their differentiation capacity

000

BioLamina @biolaminaab.bsky.social · 21/11/2024

We're looking forward to sharing, learning, and working together here! We'd like to invite you to our webinar. Experts will discuss the latest advancements in #PSC therapy, sharing insights into how it is already transforming vision restoration, and what lies ahead ⏬ tinyurl.com/ajrh3k64 #stemcell

BioLamina will have a webinar on December 10 (4–5 pm CET) on "Treating Blindness with Stem Cell Therapies". The speakers are Laura Koivusalo, PhD, CEO and Founder, StemSight Oy, Finland;
Anders Kvanta, PhD, Ophthalmologist, Vitreoretinal Surgeon, and Retinal Disease Researcher, St Erik Eye Hospital, Sweden;
Fredrik Lanner, PhD, Assistant Professor, Stem Cell Biologist, Karolinska Institute, Sweden; Stijn Heessen, PhD, Chief Operations Officer, Alder Therapeutics AB, Sweden; Kristian Tryggvason, PhD, MBA, CEO and Founder, Alder Therapeutics AB, Sweden, and Susanna Teppo, PhD, Scientific Marketing Specialist, BioLamina AB, Sweden.

Welcome!

010